OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Friedman on the Mechanism of Action of Selinexor in Multiple Myeloma

April 4th 2020

Robb S. Friedman, MD, discusses the mechanism of action of selinexor in multiple myeloma.

Dr. Fendler on Rationale for Creating the 68Ga-PSMA-11 PET in Prostate Cancer

April 4th 2020

Wolfgang Fendler, MD, discusses the rationale for creating the 68Ga-PSMA-11 PET in prostate cancer.

Dr. Armaghany on Frontline Sorafenib Versus Lenvatinib in Unresectable HCC

April 4th 2020

Tannaz Armaghany, MD, discusses sorafenib versus lenvatinib as first-line therapy for patients with hepatocellular carcinoma.

Dr. Simeone on Selecting Patients With Pancreatic Cancer for Neoadjuvant Therapy

April 4th 2020

Diane M. Simeone, MD, explains which patients with pancreatic cancer should receive neoadjuvant therapy.

Dr. Raphael on Addressing the Risk of Tumor Lysis Syndrome in CLL

April 4th 2020

Bruce G. Raphael, MD, discusses the risk of tumor lysis syndrome in chronic lymphocytic leukemia.

Dr. Choi on the Utility of Duvelisib in CLL

April 4th 2020

Michael Choi, MD, discusses the utility of duvelisib in chronic lymphocytic leukemia.

Dr. Pant on Choosing Therapy for Frontline and Beyond in Pancreatic Cancer

April 3rd 2020

Shubham Pant, MD, discusses choosing therapy for the frontline and beyond in pancreatic cancer.

Dr. Olawaiye on the Role of Surgery in Newly Diagnosed Ovarian Cancer

April 3rd 2020

Alexander B. Olawaiye, MD, discusses the role of surgery in women with newly diagnosed ovarian cancer.

Dr. Gomella on Potential Impact of Targeted Therapy Approvals on Genetic Testing in Prostate Cancer

April 3rd 2020

Leonard G. Gomella, MD, professor, chair of the Department of Urology, and director of the Sidney Kimmel Cancer Center Network, of Thomas Jefferson University Hospital, discusses the potential impact of targeted therapy approvals on the use of genetic testing in prostate cancer.

Dr. Hamid on the Evolution of Precision Medicine in Prostate Cancer

April 3rd 2020

Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses the evolution of precision medicine in prostate cancer.

Dr. Kalinksy on pCR as a Surrogate Marker for EFS in TNBC

April 3rd 2020

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses the use of pathologic complete response (pCR) rate as a surrogate marker for event-free survival (EFS) in triple-negative breast cancer (TNBC).

Dr. Jain on Treatment Options for Patients With Myelofibrosis Who Progress After Transplant

April 3rd 2020

Tania Jain, MBBS, discusses treatment options for patients with myelofibrosis who progress following allogeneic stem cell transplant.

Dr. Braunstein on Transplant Eligibility in Multiple Myeloma

April 3rd 2020

Marc J. Braunstein, MD, PhD, discusses transplant eligibility in multiple myeloma.

Dr. Iyer on Challenges With Selecting Patients With Bladder Cancer for FGFR Inhibitors

April 3rd 2020

Gopa Iyer, MD, discusses the challenges faced with identifying an optimal screening methodology to select patients with bladder cancer for FGFR inhibitor therapy.

Dr. Mehrazin on Findings From the CARMENA Trial in Metastatic RCC

April 3rd 2020

Reza Mehrazin, MD, discusses the findings of the phase III CARMENA trial in metastatic renal-cell carcinoma.

Dr. Moore on Early-Phase Data With Mirvetuximab Soravtansine in Ovarian Cancer

April 3rd 2020

Kathleen Moore, MD, discusses the early phase data that led to the development of the phase III FORWARD I/ GOG 3011 trial in ovarian cancer.

Dr. Choi on Impact of Frontline Treatment Decisions on Relapsed/Refractory CLL

April 3rd 2020

Michael Choi, MD, discusses how up-front treatment decisions impact what options can be given in the relapsed/refractory setting for patients with chronic lymphocytic leukemia.

Dr. Lin on CNS Activity With HER2-Directed TKIs in HER2+ Breast Cancer

April 2nd 2020

Nancy U. Lin, MD, discusses central nervous system activity with HER2-directed TKIs in HER2-positive breast cancer.

Dr. Miklos on the Safety Profile of KTE-X19 in MCL

April 2nd 2020

David Miklos, MD, discusses the safety profile of KTE-X19 in mantle cell lymphoma.

Dr. Park on Ongoing Research Efforts With CAR T-Cell Therapies in ALL

April 2nd 2020

Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of CAR T-cell therapies in patients with acute lymphocytic leukemia.